Listed pharmaceutical company Gedeon Richter is beating analysts’ expectations for strong revenue and profit in the second quarter, according to business daily Világgazdaság.
According to the VG consensus, analysts expected revenue of HUF 143.5 billion, while the pharmaceutical company made HUF 155.9 billion, 13.6% more than in the previous year. the reference period. The gross margin was 56.6%.
The group spent HUF 27.7 billion on pharmaceutical marketing, up 12.6 percent from a year ago, and research and development spending increased by a similar amount to HUF 16 billion. Based on all this, operating profit also improved significantly, increasing by 34% to HUF 36.4 billion, although experts expected it to rise to HUF 28.2. billion.
Seeing the development of currency effects, we could wrap up that the second quarter is not very profitable on the financial plan, less HUF 6.1 billion in the end.
SUPPORT BUDAPEST BUSINESS JOURNAL
Producing worthy journalism is an expensive endeavor. For 27 years, the editors, editors and journalists of the Budapest Business Journal have strived to bring you business news that works – information that is reliable, factual, accurate and presented without fear or favor.
News organizations around the world have struggled to find a business model that allows them to continue to excel, without compromising their ability to perform. More recently, some have experimented with the idea of involving their most important stakeholders, their readers.
We would like to offer this same opportunity to our readers. We would like to invite you to help us provide the quality business journalism you need. Hit our Support BBJ button and you can choose how much and how often you send us your contributions.